194 related articles for article (PubMed ID: 14528099)
1. Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
Smith SC; Lindsley SK; Felgenhauer J; Hawkins DS; Douglas JG
J Pediatr Hematol Oncol; 2003 Oct; 25(10):774-9. PubMed ID: 14528099
[TBL] [Abstract][Full Text] [Related]
2. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
Douglas JG; Arndt CA; Hawkins DS
Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885
[TBL] [Abstract][Full Text] [Related]
3. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival.
Eaton BR; McDonald MW; Kim S; Marcus RB; Sutter AL; Chen Z; Esiashvili N
Cancer; 2013 Apr; 119(8):1578-85. PubMed ID: 23280478
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
6. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
7. Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation.
Paulino AC; Bauman N; Simon JH; Nguyen TX; Ritchie JM; Tannous R
Med Pediatr Oncol; 2003 Aug; 41(2):118-22. PubMed ID: 12825215
[TBL] [Abstract][Full Text] [Related]
8. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997.
Raney RB; Meza J; Anderson JR; Fryer CJ; Donaldson SS; Breneman JC; Fitzgerald TJ; Gehan EA; Michalski JM; Ortega JA; Qualman SJ; Sandler E; Wharam MD; Wiener ES; Maurer HM; Crist WM
Med Pediatr Oncol; 2002 Jan; 38(1):22-32. PubMed ID: 11835233
[TBL] [Abstract][Full Text] [Related]
9. Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study Group.
Walterhouse DO; Pappo AS; Baker KS; Parham DM; Anderson JR; Donaldson SS; Paidas CN; Womer RB; Crist WM
Cancer; 2001 Dec; 92(12):3135-46. PubMed ID: 11753993
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial evaluating selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma.
Regine WF; Fontanesi J; Kumar P; Zeitzer K; Greenwald C; Bowman L; Shapiro DN; Rao BN; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):799-805. PubMed ID: 7860391
[TBL] [Abstract][Full Text] [Related]
11. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
Childs SK; Kozak KR; Friedmann AM; Yeap BY; Adams J; MacDonald SM; Liebsch NJ; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):635-42. PubMed ID: 21377294
[TBL] [Abstract][Full Text] [Related]
12. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma.
Raney B; Tefft M; Heyn R; Newton W; Jones PM; Haeberlen V; Maurer H
Cancer; 1992 Mar; 69(6):1498-506. PubMed ID: 1540886
[TBL] [Abstract][Full Text] [Related]
13. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
[TBL] [Abstract][Full Text] [Related]
14. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
[TBL] [Abstract][Full Text] [Related]
15. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.
Michalski JM; Meza J; Breneman JC; Wolden SL; Laurie F; Jodoin M; Raney B; Wharam MD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1027-38. PubMed ID: 15234036
[TBL] [Abstract][Full Text] [Related]
16. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
[TBL] [Abstract][Full Text] [Related]
17. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
18. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
20. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M;
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
